Digitisation | January 10, 2026
Revvity and Lilly partner to accelerate AI drug discovery models
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
New AI capabilities will help scientists identify, optimize, and validate new molecules. Additional applications include manufacturing, medical imaging, and enterprise AI agents
82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Subscribe To Our Newsletter & Stay Updated
